In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Conatus Pharmaceuticals Inc.. Trade Record

NASDAQ:CNAT Conatus Pharmaceuticals Inc. stock gains 31.89% Exit Jun 21, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CNAT May 30, 2018, priceSeries
About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

Trade Information
Trade Type
Entry Date
May 30, 2018
Entry Price
Sell Date
Jun 21, 2018
Sell Price
Net Gain
Hold Time
16 Trading Days